Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzolamide vs timolol in open-angle glaucoma or ocular hypertension poorly controlled on timolol monotherapy
CTR20160089Phase 3Suspended
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dorzolamide in open-angle glaucoma (OAG), pigmentary glaucoma (PG), pseudoexfoliation glaucoma (PXG), ocular hypertension, sponsored by Merck & Co.. Started Feb 2016; status: suspended.
02
Drugs
dorzolamide
03
Conditions
open-angle glaucoma (OAG)pigmentary glaucoma (PG)pseudoexfoliation glaucoma (PXG)ocular hypertension
Beyond the preview
Go deeper on CTR20160089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160089.